Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями
https://doi.org/10.17650/1818-8346-2022-17-3-127-136
Аннотация
Кардиоонкология возникла как новая область на стыке кардиологии и онкологии. Повышение эффективности противоопухолевого лечения увеличило выживаемость онкологических гематологических пациентов, однако долгосрочные сердечно-сосудистые последствия этого лечения стали более клинически значимыми.
Несмотря на эффективность современных методов лечения, некоторые препараты, такие как ингибиторы киназы Bcr-Abl, антрациклины, ингибиторы HER2/Erbb2, ингибиторы фактора роста эндотелия сосудов, фторпиримидины, а также лучевая терапия могут оказывать выраженное влияние на сердечно-сосудистую систему. Токсические эффекты приводят к нарушению ритма сердца, сердечной недостаточности, сосудистой токсичности и даже смерти. Для гематологов, онкологов и кардиологов важно понимать основные стратегии диагностики и лечения, которые следует использовать при возникновении подобной токсичности.
Об авторах
Л. М. Когония
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского
Россия
Россия
129110 Москва, ул. Щепкина, 61 / 2, корп. 1.
М. О. Русанов
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского
Россия
Россия
Русанов Максим Олегович.
129110 Москва, ул. Щепкина, 61 / 2, корп. 1.
В. Е. Шикина
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского
Россия
Россия
129110 Москва, ул. Щепкина, 61 / 2, корп. 1.
Список литературы
1. Moslehi J.J., Salem J.E., Sosman J.A. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391(10124):933. DOI: 10.1016/S0140-6736(18)30533-6
2. Lin L., Yan L., Liu Y. et al. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol 2019;12(1):96. DOI: 10.1186/s13045-019-0783-9
3. Cardinale D., Colombo A., Bacchiani G. et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015;131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777
4. Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749-55. DOI: 10.1056/NEJMoa1609214
5. Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Злокачественные опухоли: Практические рекомендации RUSSCO 2021;11(3s2):78-98. DOI: 10.18027/2224-5057-2021-11-3s2-41
6. Lancellotti P., Suter T.M., Lopez-Fernandez T. et al. Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 2019;40(22):1756-63. DOI: 10.1093/eurheartj/ehy453
7. Yancy C.W., Jessup M., Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):1810-52. DOI: 10.1161/CIR.0b013e31829e8807
8. Seidman A., Hudis C., Pierri M.K. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. DOI: 10.1200/JCO.2002.20.5.1215
9. Perez I.E., Taveras Alam S., Hernandez G.A., Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol 2019;13:1179546819866445. DOI: 10.1177/1179546819866445
10. Von Hoff D.D., Layard M.W., Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710-7. DOI: 10.7326/0003-4819-91-5-710
11. Yeh E.T., Tong A.T., Lenihan D.J. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109(25): 3122-31. DOI: 10.1161/01.CIR.0000133187.74800.B9
12. Volkova M., Russell R.3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7(4):214-20. DOI: 10.2174/157340311799960645
13. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11): 2869-79. DOI: 10.1002/cncr.11407
14. Chang H.M., Moudgil R., Scarabelli T. et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol 2017;70(20):2536-51. DOI: 10.1016/j.jacc.2017.09.1096
15. McGowan J.V., Chung R., Maulik A. et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017;31(1):63-75. DOI:10.1007/s10557-016-6711-0
16. Curigliano G., Cardinale D., Suter T. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii155-66. DOI: 10.1093/annonc/mds293
17. Fallah-Rad N., Walker J.R., Wassef A. et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57(22):2263-70. DOI: 10.1016/j.jacc.2010.11.063
18. Rosa G.M., Gigli L., Tagliasacchi M.I. et al. Update on cardiotoxicity of anticancer treatments. Eur J Clin Invest 2016; 46(3):264-84. DOI: 10.1111/eci.12589
19. Markman T.M., Ruble K., Loeb D. et al. Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy. Pediatr Blood Cancer 2017;64(11). DOI: 10.1002/pbc.26556
20. Van Dalen E.C., van der Pal H.J., Kremer L.C. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2016;3(3):CD005008. DOI: 10.1002/14651858.CD005008.pub4
21. Smith D.H., Adams J.R., Johnston S.R. et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 2002;13(10): 1590-7. DOI: 10.1093/annonc/mdf275
22. Van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;(2):CD003917. DOI: 10.1002/14651858.CD003917.pub3
23. Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62. DOI: 10.1016/j.jacc.2013.02.072
24. Schuchter L.M., Hensley M.L., Meropol N.J. et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20(12):2895-903. DOI: 10.1200/JCO.2002.04.178
25. Renehan A.G., Tyson M., Egger M. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X
26. Kenchaiah S., Sesso H.D., Gaziano J.M. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009;119(1):44-52. DOI: 10.1161/CIRCULATIONAHA.108.807289
27. Kenchaiah S., Chesebro J.H. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn 2017;49(8):4-6.
28. Kwakman J.J., Simkens L.H., Mol L. et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer 2017;76:93-9. DOI: 10.1016/j.ejca.2017.02.009
29. Li W., Croce K., Steensma D.P. et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66(10):1160-78. DOI: 10.1016/j.jacc.2015.07.025
30. Mitra M.S., Donthamsetty S., White B., Mehendale H.M. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 2008;231(3):413-22. DOI: 10.1016/j.taap.2008.05.006
31. Guenancia C., Hachet O., Aboutabl M. et al. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol 2016;77(4):777-85. DOI: 10.1007/s00280-016-2995-9
32. Bosch X., Rovira M., Sitges M. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61(23):2355-62. DOI: 10.1016/j.jacc.2013.02.072
33. Majed B., Moreau T., Senouci K. et al. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat 2008;111(2):329-42. DOI: 10.1007/s10549-007-9785-3
34. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579-91. DOI: 10.1038/nrc1408
35. Slamon D., Eiermann W., Robert N. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365(14): 1273-83. DOI: 10.1056/NEJMoa0910383
36. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO 2020;10(3s2-1):145-82. DOI: 10.18027/2224-5057-2020-10-3s2-09
37. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37(29): 2315-81. DOI: 10.1093/eurheartj/ehw106
38. Labianca R., Beretta G., Clerici M. et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68(6):505-10.
39. Kabore E.G., Guenancia C., Vaz-Luis I. et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 2019;16(12):e1002989. DOI: 10.1371/journal.pmed.1002989
40. Campia U., Moslehi J.J., Amiri-Kordes-tani L. et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the american heart association. Circulation 2019;139(13):e579-602. DOI: 10.1161/CIR.0000000000000641
41. Cameron A.C., Touyz R.M., Lang N.N. Vascular complications of cancer chemotherapy. Can J Cardiol 2016;32(7):852-62. DOI: 10.1016/j.cjca.2015.12.023
42. Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardio-logy/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;140(11):e596-646. DOI: 10.1161/CIR.0000000000000678
43. Singh A.P., Glennon M.S., Umbarkar P. et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 2019;115(5):966-77. DOI: 10.1093/cvr/cvz006
44. Aichberger K.J., Herndlhofer S., Schernthaner G.H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86(7):533-9. DOI: 10.1002/ajh.22037
45. Hochhaus A., Baccarani M., Silver R.T. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34(4): 966-84. DOI: 10.1038/s41375-020-0776-2
46. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48(1):9-17. DOI: 10.1080/02841860802314720
47. Maitland M.L., Bakris G.L., Black H.R. et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102(9):596-604. DOI: 10.1093/jnci/djq091
48. Salem J.E., Manouchehri A., Moey M. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19(12):1579-89. DOI: 10.1016/S1470-2045(18)30608-9
49. Johnson D.B., Balko J.M., Compton M.L. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016;375(18):1749-55. DOI: 10.1056/NEJMoa1609214
50. Geisler B.P., Raad R.A., Esaian D. et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 2015; 3:4. DOI: 10.1186/s40425-015-0048-2
51. Anderson R.D., Brooks M. Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy. Int J Cardiol 2016;222:760-1. DOI: 10.1016/j.ijcard.2016.07.291
52. Heinzerling L., Ott P.A., Hodi F.S. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer 2016;4:50. DOI: 10.1186/s40425-016-0152-y
53. Ederhy S., Cautela J., Ancedy Y. et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(8):1187-90. DOI: 10.1016/j.jcmg.2017.11.036
54. Roth M.E., Muluneh B., Jensen B.C. et al. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23(6):e1925-8. DOI: 10.1097/MJT.0000000000000430
55. Weinstock C., Khozin S., Suzman D. et al. U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res 2017;23(16):4534-9. DOI: 10.1158/1078-0432.CCR-17-0540
56. Nykl R., Fischer O., Vykoupil K., Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) -systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis 2017;2:e100-2. DOI: 10.5114/amsad.2017.72531
57. Lenneman C.G., Sawyer D.B. Cardiooncology: an update on cardiotoxicity of cancer-related treatment. Circ Res 2016;118(6):1008-20. DOI: 10.1161/CIRCRESAHA.115.303633
58. Rygiel K. Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: an overview. J Cancer Res Ther 2017;13(2):186-92. DOI: 10.4103/0973-1482.187303
59. Niska J.R., Thorpe C.S., Allen S.M. et al. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Expert Rev Cardiovasc Ther 2018;16(12):931-50. DOI: 10.1080/14779072.2018.1538785
60. Yeboa D.N., Evans S.B. Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol 2016;26(1):71-8. DOI: 10.1016/j.semradonc.2015.09.003
61. Domercant J., Polin N., Jahangir E. Cardio-oncology: a focused review of an-thracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J 2016;16(3):250-6.
62. Adams M.J., Lipsitz S.R., Colan S.D. et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22(15):3139-48. DOI: 10.1200/JCO.2004.09.109
63. Lancellotti P., Nkomo V.T., Badano L.P. et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013;14(8):721-40. DOI: 10.1093/ehjci/jet123
64. Swanson T., Grills I.S., Ye H. et al. Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in leftsided breast irradiation for patients with early-stage or locally advanced breast cancer. Am J Clin Oncol 2013;36(1):24-30. DOI: 10.1097/COC.0b013e31823fe481
65. Menezes K.M., Wang H., Hada M., Saganti P.B. Radiation matters of the heart: a mini review. Front Cardiovasc Med 2018;5:83. DOI: 10.3389/fcvm.2018.0008
66. Boyle J., Ackerson B., Gu L., Kelsey C.R. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer. Adv Radiat Oncol 2017;2(1):6-11. DOI: 10.1016/j.adro.2016.12.006
67. Chun S.G., Hu C., Choy H. et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35(1):56-62. DOI: 10.1200/JCO.2016.69.1378
Рецензия
Для цитирования:
Когония Л.М., Русанов М.О., Шикина В.Е. Кардиотоксичность противоопухолевых препаратов и лучевой терапии у пациентов со злокачественными заболеваниями крови и сóлидными злокачественными новообразованиями. Онкогематология. 2022;17(3):127-136. https://doi.org/10.17650/1818-8346-2022-17-3-127-136
For citation:
Kogoniya L.M., Rusanov M.O., Shikina V.E. Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. Oncohematology. 2022;17(3):127-136. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-3-127-136
Просмотров:
9315
Послать статью по эл. почте 